fda glp 1 shortage semaglutide status january 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list GLP-1 No Longer on FDA's – FDA says shortage of GLP-1

This "paradoxical response" (where treatment temporarily makes symptoms worse) includes: Numbness and tingling Shooting pains Joint pain Increased sensitivity Temporary inflammation (swelling and irritation) While these symptoms generally indicate that treatment is working (as nerves begin to repair themselves), they can be distressing for patients and may require additional treatment for comfort

Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives

Not exactly music to the ears

Each category has its own formulary, its own coverage rules, and its own prior authorization requirements for GLP-1 fat loss treatment

Lei C, Niu X, Wei J, Zhu J, Zhu Y